Aramark, Whirlpool, Grainger, Kraft Heinz, Ralph Lauren & Sterling Jewelers sued UnitedHealth for overpaying medical claims, ...
Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...
Researchers had been testing whether Artiva's off-the-shelf NK cell therapy called AB-101 could treat rheumatoid arthritis and other autoimmune diseases.
Q3 Biopharma Sentiment Index shows regulatory optimism rising after Marty Makary and Vinay Prasad's FDA exits, though scientists remain pessimistic.
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
WuXi AppTec raises 2026 guidance again as Q3 revenue jumps 38% to $2.5B, despite its fight over the Pentagon’s Chinese military designation ...
Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Editor’s note: Longtime oncology R&D expert ...
Arsalan Arif is the founder and CEO of Endpoints News. Since launching the company in 2016 with John Carroll, Arsalan built Endpoints into a global newsroom of more than 70 journalists and media ...
Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, ...
Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results